Otonomy Announces Proposed Public Offering
07. April 2021 16:06 ET
|
Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Provides Corporate and Product Pipeline Update
03. Januar 2019 07:30 ET
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
Otonomy to Present at the J.P. Morgan Healthcare Conference
02. Januar 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
15. November 2018 08:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David...
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06. November 2018 07:30 ET
|
Otonomy, Inc.
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company...
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05. November 2018 16:12 ET
|
Otonomy, Inc.
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, Nov. 05, 2018...
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
30. Oktober 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple...
Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
29. Oktober 2018 07:30 ET
|
Otonomy, Inc.
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the...
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
02. Oktober 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
25. September 2018 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...